Vivek Subbiah: Thrilled to present at ESMO 2025 on Tumour-Agnostic Drug Development in Precision Medicine
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Bonjour from the City of Light!
Thrilled to have arrived in Paris, France, for the ESMO TAT Symposium 2025 – a hub of innovation and collaboration for new drugs and latest and greatest in oncology.
It’s an incredible honor to be invited to deliver the Keynote lecture at such a prestigious meeting.
Join me today as I explore the topic ‘Revolutionising Cancer Treatment: The Transformative Odyssey of Tumour-Agnostic Drug Development in Precision Medicine.’
Together, we’ll explore the groundbreaking advancements reshaping cancer therapy and the promise they hold for patients worldwide.
- When: Tuesday, March 4th, 2025
- Time: 14:00- 14:55
Looking forward to sharing insights and engaging with fellow pioneers in this exciting field.
Thanks to the organizers for the invite to talk and the forward-thinking visionary meeting.
Let’s continue to push the boundaries of what’s possible in cancer treatment!”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023